Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
5397 | 1562 | 42.6 | 86% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | UTP | Author keyword | 32 | 33% | 5% | 80 |
2 | P2Y RECEPTORS | Author keyword | 28 | 35% | 4% | 66 |
3 | MOL RECOGNIT SECT | Address | 25 | 26% | 5% | 84 |
4 | NUCLEOTIDE RECEPTORS | Author keyword | 20 | 47% | 2% | 31 |
5 | P2X1 | Author keyword | 19 | 63% | 1% | 19 |
6 | P2Y14 | Author keyword | 18 | 89% | 1% | 8 |
7 | P2Y14 RECEPTOR | Author keyword | 17 | 100% | 1% | 8 |
8 | P2Y1 RECEPTOR | Author keyword | 16 | 44% | 2% | 28 |
9 | P2Y11 RECEPTOR | Author keyword | 15 | 88% | 0% | 7 |
10 | UP4A | Author keyword | 15 | 88% | 0% | 7 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | UTP | 32 | 33% | 5% | 80 | Search UTP | Search UTP |
2 | P2Y RECEPTORS | 28 | 35% | 4% | 66 | Search P2Y+RECEPTORS | Search P2Y+RECEPTORS |
3 | NUCLEOTIDE RECEPTORS | 20 | 47% | 2% | 31 | Search NUCLEOTIDE+RECEPTORS | Search NUCLEOTIDE+RECEPTORS |
4 | P2X1 | 19 | 63% | 1% | 19 | Search P2X1 | Search P2X1 |
5 | P2Y14 | 18 | 89% | 1% | 8 | Search P2Y14 | Search P2Y14 |
6 | P2Y14 RECEPTOR | 17 | 100% | 1% | 8 | Search P2Y14+RECEPTOR | Search P2Y14+RECEPTOR |
7 | P2Y1 RECEPTOR | 16 | 44% | 2% | 28 | Search P2Y1+RECEPTOR | Search P2Y1+RECEPTOR |
8 | P2Y11 RECEPTOR | 15 | 88% | 0% | 7 | Search P2Y11+RECEPTOR | Search P2Y11+RECEPTOR |
9 | UP4A | 15 | 88% | 0% | 7 | Search UP4A | Search UP4A |
10 | P2 RECEPTORS | 13 | 21% | 4% | 55 | Search P2+RECEPTORS | Search P2+RECEPTORS |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | NUCLEOTIDE RECEPTORS | 66 | 39% | 9% | 135 |
2 | P2Y1 RECEPTOR | 55 | 47% | 6% | 86 |
3 | P 2Y PURINOCEPTOR AGONISTS | 52 | 100% | 1% | 18 |
4 | URIDINE NUCLEOTIDE RECEPTOR | 46 | 72% | 2% | 36 |
5 | UTP | 45 | 47% | 5% | 72 |
6 | P2 RECEPTORS | 38 | 31% | 7% | 105 |
7 | ADP RECEPTOR | 38 | 45% | 4% | 64 |
8 | INHIBITS ADENYLATE CYCLASE | 38 | 93% | 1% | 14 |
9 | GPR105 KIAA0001 | 34 | 93% | 1% | 13 |
10 | PURINOCEPTORS | 30 | 23% | 7% | 114 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Molecular pharmacology of P2Y-receptors | 2000 | 335 | 125 | 78% |
International union of pharmacology LVIII: Update on the P2Y G protein-coupled nucleotide receptors: From molecular mechanisms and pathophysiology to therapy | 2006 | 491 | 547 | 48% |
Pharmacological profiles of cloned mammalian P2Y-receptor subtypes | 2006 | 291 | 203 | 65% |
P2Y nucleotide receptors: promise of therapeutic applications | 2010 | 52 | 83 | 61% |
P2 receptors in cardiovascular regulation and disease | 2008 | 148 | 197 | 32% |
Signalling and pharmacological properties of the P2Y(14) receptor | 2010 | 27 | 62 | 65% |
P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells | 2012 | 28 | 129 | 34% |
Advances in signalling by extracellular nucleotides: the role and transduction mechanisms of P2Y receptors | 2000 | 115 | 144 | 63% |
ADP receptors and clinical bleeding disorders | 1999 | 102 | 28 | 82% |
P2 receptors: intracellular signaling | 2006 | 138 | 147 | 46% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MOL RECOGNIT SECT | 25 | 26% | 5.4% | 84 |
2 | LIFE SCI 540E | 12 | 86% | 0.4% | 6 |
3 | GONDA GOLD MIED MED | 11 | 47% | 1.1% | 17 |
4 | BIOL PHARMACOL HEMOSTASE THROMBOSE | 9 | 83% | 0.3% | 5 |
5 | BOND LIFE SCI 540E | 8 | 100% | 0.3% | 5 |
6 | U311 | 6 | 21% | 1.7% | 26 |
7 | MOL CELLULAR PHARMACOL PURINERG TRANSMISS | 4 | 31% | 0.7% | 11 |
8 | ESTAB FRANCAIS SANG ALSACE | 3 | 60% | 0.2% | 3 |
9 | MOL VET BIOSCI PROGRAM | 2 | 67% | 0.1% | 2 |
10 | COMPUTAT CHEM CORE | 2 | 50% | 0.2% | 3 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000240917 | P2X7 RECEPTOR//P2X7//P2X RECEPTORS |
2 | 0.0000139179 | COTRANSMISSION//GUINEA PIG VAS DEFERENS//P 2X PURINOCEPTOR |
3 | 0.0000111763 | AP4A//DIADENOSINE TETRAPHOSPHATE//DIADENOSINE POLYPHOSPHATES |
4 | 0.0000101916 | KW 3902//2 3 CAMP//ADENOSINE A1 RECEPTOR ANTAGONIST |
5 | 0.0000100082 | NTPDASE//ATP DIPHOSPHOHYDROLASE//ECTO ATPASE |
6 | 0.0000081109 | GLYCOPROTEIN VI//GPVI//CLEC 2 |
7 | 0.0000067014 | CL EXTRACELLULAR//RB 86 FLUX//RECEPTOR OPERATED CA2 CHANNEL |
8 | 0.0000058271 | CLOPIDOGREL//PRASUGREL//TICAGRELOR |
9 | 0.0000057647 | COUPLING FACTOR 6//DISCOVERY BIOTECHNOL 2//BIOPHARMA |
10 | 0.0000053676 | HUMAN PLATELET//PLATELETS HUMAN//ATPASE CA2 MG2 |